Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
006280KOSPI·Nov 04, 2025
3Q25 review: In-line results
Mirae Asset Securities published a company analysis report on GC Biopharma Corp. (006280) titled "3Q25 review: In-line results".
Summary
Covers GC Biopharma Corp. (006280).
Covered stock
More on 006280
2Q26 preview: Earnings set to improve in 2HMirae Asset Securities · Jul 23, 2026Alyglo performance beats expectationsMirae Asset Securities · May 11, 20264Q25 preview: Alyglo growth to ease concernsMirae Asset Securities · Jan 16, 20262Q25 results likely to ease concernsMirae Asset Securities · Jul 23, 2025Earnings improve on increased sales of high-margin productsMirae Asset Securities · May 07, 2025Profit turnaround expected on favorable product mixMirae Asset Securities · Apr 17, 2025